Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 156 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Acalabrutinib with Venetoclax for CLL or SLL No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours MOST POPULAR FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell... December 3, 2024 How could proposed changes to data protection laws affect research? December 8, 2021 Embedding research integrity at the core of our science July 28, 2021 Are New Immune-Based Treatments for Kidney and Pancreatic Cancer on the... April 23, 2025 Load more HOT NEWS Omission of Surgical Axillary Staging Noninferior To Sentinel Lymph Node Biopsy... What Are Clinical Practice Guidelines and How Do They Impact Care... Finding Hope in the New Year During COVID-19 and Cancer Dwayne Johnson Sends Special “Moana” Message To 3-Yr-Old Battling Cancer.
